Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Most charming and powerful

Tuesday, February 17, 2015

The newspaper “Pharmaceutical herald” and RNC Pharma once again summarize the rating of the most influential subjects on the Russian pharmaceutical market. Within the study, 630 respondents’ opinions in 36 regions of Russia were interviewed. This time our experts defined the best of the best in 10 nominations:

  • - Local pharmaceuticals manufacturers,
  • - Foreign pharmaceuticals manufacturers,
  • - Distribution companies,
  • - Pharmacy chains,
  • - Entrepreneurs, general managers of commercial structures,
  • - Government/Social activists, scientists,
  • - Professional non-commercial associations,
  • - Internet sites,
  • - Specialized pharmaceutical periodical media,
  • - The most popular drug

Among governmental and social figures, the third year in the row, respondents call the Minister of Healthcare, Veronika Skvortsova the most influential person. The most popular prescription medication in 2014 is Aktovegin (TAKEDA) and among non-prescription drugs the leader, second year in a row, is russian drug Kagocel (NIARMEDIC PLUS).

Detailed results of the first project part are published in the “Pharmaceutical herald” №5, 17 February 2015. To be continued in №6, 24 February 2015.

Share: